MX394171B - Una composicion farmaceutica que comprende racecadotrilo y procedimiento para preparar la misma - Google Patents

Una composicion farmaceutica que comprende racecadotrilo y procedimiento para preparar la misma

Info

Publication number
MX394171B
MX394171B MX2018014260A MX2018014260A MX394171B MX 394171 B MX394171 B MX 394171B MX 2018014260 A MX2018014260 A MX 2018014260A MX 2018014260 A MX2018014260 A MX 2018014260A MX 394171 B MX394171 B MX 394171B
Authority
MX
Mexico
Prior art keywords
racecadotril
preparing
same
pharmaceutical composition
relates
Prior art date
Application number
MX2018014260A
Other languages
English (en)
Other versions
MX2018014260A (es
Inventor
Amol Y Chaudhari
Mahendra B Chaudhari
Nitin P Nehete
Original Assignee
Athena Pharmaceutiques Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63447638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX394171(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Athena Pharmaceutiques Sas filed Critical Athena Pharmaceutiques Sas
Publication of MX2018014260A publication Critical patent/MX2018014260A/es
Publication of MX394171B publication Critical patent/MX394171B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende racecadotrilo y azúcar cocristalizado y a un procedimiento para preparar la misma.
MX2018014260A 2017-03-06 2018-02-20 Una composicion farmaceutica que comprende racecadotrilo y procedimiento para preparar la misma MX394171B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721007797 2017-03-06
PCT/IN2018/050085 WO2018163195A1 (en) 2017-03-06 2018-02-20 A pharmaceutical composition comprising racecadotril and process for preparing the same

Publications (2)

Publication Number Publication Date
MX2018014260A MX2018014260A (es) 2019-04-29
MX394171B true MX394171B (es) 2025-03-24

Family

ID=63447638

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014260A MX394171B (es) 2017-03-06 2018-02-20 Una composicion farmaceutica que comprende racecadotrilo y procedimiento para preparar la misma

Country Status (10)

Country Link
US (1) US20200061014A1 (es)
EP (1) EP3592333B1 (es)
KR (1) KR102195776B1 (es)
CN (1) CN108834401A (es)
BR (1) BR112018069973A2 (es)
ES (1) ES2978020T3 (es)
MX (1) MX394171B (es)
PL (1) PL3592333T3 (es)
RU (1) RU2749949C2 (es)
WO (1) WO2018163195A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US6214402B1 (en) * 1998-09-17 2001-04-10 The Nutrasweet Company Co-crystallization of sugar and n-[n-(3,3-dimethylbutyl)-l αaspartyl]-l-phenylalanine 1-methyl ester
ES2247163T3 (es) 2000-06-23 2006-03-01 Bioprojet Formulacion en polvo seca que comprende racedotril.
GB0015490D0 (en) * 2000-06-23 2000-08-16 Smithkline Beecham Lab Novel formulations
KR20120048046A (ko) * 2004-02-06 2012-05-14 세파론, 인코포레이티드 모다피닐 조성물
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
WO2007144683A1 (es) * 2006-06-13 2007-12-21 Ingenio Del Cauca S.A. - Incauca S.A. Proceso de co-cristalización de sacarosa y un edulcorante natural y el producto obtenido
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
ES2600628T3 (es) * 2012-06-28 2017-02-10 Johnson & Johnson Consumer Inc. Composición líquida de racecadotril
TR201801726T4 (tr) * 2012-12-26 2018-03-21 Ilko Ilac Sanayi Veticaret A S Rasekadotri̇l ve farmasöti̇k bi̇leşi̇mleri̇.
CN104224724A (zh) * 2013-06-08 2014-12-24 北京韩美药品有限公司 一种消旋卡多曲颗粒剂及其制备工艺
CN103565750A (zh) * 2013-09-30 2014-02-12 北京德众万全药物技术开发有限公司 消旋卡多曲颗粒及其制备方法
EP2949318A1 (en) * 2014-05-26 2015-12-02 Galenicum Health S.L. Pharmaceutical compositions comprising racecadotril
MA40859A (fr) * 2014-10-29 2017-09-05 Johnson & Johnson Consumer Inc Particules de cadotril

Also Published As

Publication number Publication date
CN108834401A (zh) 2018-11-16
US20200061014A1 (en) 2020-02-27
KR20180129807A (ko) 2018-12-05
RU2749949C2 (ru) 2021-06-21
WO2018163195A1 (en) 2018-09-13
MX2018014260A (es) 2019-04-29
EP3592333B1 (en) 2024-04-03
EP3592333A1 (en) 2020-01-15
EP3592333C0 (en) 2024-04-03
ES2978020T3 (es) 2024-09-04
EP3592333A4 (en) 2020-08-19
RU2018131133A (ru) 2021-01-22
RU2018131133A3 (es) 2021-01-22
BR112018069973A2 (pt) 2019-09-17
PL3592333T3 (pl) 2024-06-17
KR102195776B1 (ko) 2020-12-29

Similar Documents

Publication Publication Date Title
ZA201802657B (en) Crystal forms of beta-nicotinamide mononucleotide
EP4620519A3 (en) Methods and compositions relating to chondrisomes from blood products
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
PH12019501970A1 (en) Pharmaceutical compositions for combination therapy
PH12019501301A1 (en) Pharmaceutical compositions for combination therapy
EP3359193A4 (en) NOVEL CARBOHYDRATIC ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
AU2018302170A1 (en) Pharmaceutical compositions comprising entrectinib
NZ728401A (en) High purity oritavancin and method of producing same
MX2017015137A (es) Composicion farmaceutica oral de dosis diaria de isotretinoin.
EP3275454A4 (en) Pharmaceutical composition containing silybin, ve and l-carnitine
PH12017502028A1 (en) Vortioxetine pyroglutamate
MX2020009444A (es) Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion.
IN2014CH00840A (es)
EP4424373A3 (en) Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
MX2017015505A (es) Composicion de preparacion solida que contiene pranlukast con biodisponibilidad mejorada y metodo para preparar la misma.
EP3720844A4 (en) MEDICINAL COMPOSITIONS
MY172656A (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
IL271513A (en) Innovative pharmaceutical composition
MX394171B (es) Una composicion farmaceutica que comprende racecadotrilo y procedimiento para preparar la misma
MY164337A (en) Chocolate
PH12017502253B1 (en) Imidazodiazepine compound
MX2020011170A (es) Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona.
HUP1800273A2 (en) Stable pharmaceutical compositions and process for the preparation thereof
HK40106821A (zh) 医药组合物
HK40107360A (zh) 用於癌症治疗的药物组合物